OMSÄTTNING OCH AKTIEKURS

I grafen visas aktiekursutveckling och omsättning för valt bolag. Informationen är fördröjd med 15 min.

Omsättning
Aktuell Kurs
Utvecklingen i dag
Rapporter | 31 May 2023 | Biosergen

Biosergen AB: Biosergen publishes…

Summary of the Interim Report for Q1 2023 2023 2022 2022TSEK Jan-Mar Jan-Mar Jan-Dec Profit/lossOther income 5,315 1,317 5,183Profit/loss before depreciation (EBITDA -5,029 -5,018 -34,129Operating profit/loss before net financials -5,029…

Läs hela nyheten
Pressreleaser | 31 May 2023 | Biosergen

Bulletin from the annual general meeting…

Resolution on adoption of accounts and allocation of the company’s resultThe annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated…

Läs hela nyheten
Pressreleaser | 10 May 2023 | Biosergen

Biosergen AB: Biosergen publishes 2022…

Biosergen CEO Peder M. Andersen commented: ”We are pleased to present Biosergen’s annual report for 2022. The most important event during the year was the successfully repeated dose escalation in…

Läs hela nyheten
Pressreleaser | 28 Apr 2023 | Biosergen

Notice of annual general meeting in…

Right to participate and notice of participation Shareholders wishing to participate in the annual general meeting must: partly be listed in the company’s share register kept by Euroclear Sweden AB…

Läs hela nyheten
Pressreleaser | 5 Apr 2023 | Biosergen

Biosergen AB: Biosergen - Minskad risk…

Biosergen avser att genomföra en fas 2a-studie för att visa den potential som BSG005 har. I studien ingår testfall med olika svampstammar vid invasiv svampsjukdom hos patienter. Undersökningen kommer att…

Läs hela nyheten
Pressreleaser | 5 Apr 2023 | Biosergen

Biosergen AB: Biosergen - Reduced risk…

Biosergen intends to conduct a phase 2a study to demonstrate the potential that BSG005 possesses. The study includes testing cases with different fungi strains in invasive fungal disease in patients.…

Läs hela nyheten
Rapporter | 31 Mar 2023 | Biosergen

Biosergen AB: Biosergen publishes…

Summary of the Interim Report for Q4 2022 2022 2021 2022 2021TSEK Oct-Dec Oct-Dec Jan-Dec Jan-Dec Other income 1.964 3.290 5.183 8.573Profit/loss before depreciation (EBITDA) -12.491 -9.876 -39.987 -34.077Operating profit/loss…

Läs hela nyheten
Pressreleaser | 29 Mar 2023 | Biosergen

Carlsquare: Mrkt BUZZ, Biosergen: Plans…

Carlsquare Equity Research comments on Biosergen’s plans for the next step in clinical development. Read the full comment here. About Carlsquare Carlsquare is a Pan-European research firm and financial advisor,…

Läs hela nyheten
Pressreleaser | 29 Mar 2023 | Biosergen

Biosergen AB: Biosergen provides Phase 2…

Biosergen is pleased to announce its plans to initiate its first Phase 2 clinical trial towards the end of Q2 2023. The multi-indication, open-label, single-center trial will be conducted at…

Läs hela nyheten
Pressreleaser | 28 Mar 2023 | Biosergen

Biosergen AB: Biosergen will be…

Läs hela nyheten

Kommande händelser

31 Aug 2023 | Kvartalsrapport 2023-Q2
30 Nov 2023 | Kvartalsrapport 2023-Q3
29 Mar 2024 | Bokslutskommuniké 2023